BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis

Islas-Hernandez, Azul; Aguilar-Talamantes, Hugo; Bertado-Cortés, Brenda; Mejia-delCastillo, Georgina de Jesus; Carrera-Pineda, Raúl; Cuevas-García, Carlos; García-delaTorre, Paola

doi:10.2217/bmm-2017-0374

Cited by 35 publications

(27 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This reduction was more pronounced in patients with SPMS. These findings at the group level are in line with some previous reports, 5,6,29 while other studies in smaller cohorts 30 did not confirm a difference.…”

Section: Discussionsupporting

confidence: 92%

“…3,4 Previous reports have also explored possible links between levels of BDNF in serum and different MS courses. 5,6 In MS lesions, at the cellular level, beyond neurons, BDNF is primarily present in immune cells including T cells and microglial cells, possibly also in reactive astrocytes. 7 A "trophic" interaction between infiltrating immune cells and neurons has been repeatedly discussed [7][8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

“…In a large number of studies, the levels of BDNF in human serum have been measured in multiple conditions including neurodegenerative and psychiatric diseases 3,4 . Previous reports have also explored possible links between levels of BDNF in serum and different MS courses 5,6 . In MS lesions, at the cellular level, beyond neurons, BDNF is primarily present in immune cells including T cells and microglial cells, possibly also in reactive astrocytes 7 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis

Naegelin

Saeuberli

Schaedelin

et al. 2020

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective: To determine the levels of brain-derived neurotrophic factor (BDNF) in the serum of patients suffering from multiple sclerosis (MS) to evaluate the potential of serum BDNF as a biomarker for MS. Methods: Using a recently validated enzyme-linked immunoassay (ELISA) we measured BDNF in patients with MS (pwMS), diagnosed according to the 2001 McDonald criteria and aged between 18 and 70 years, participating in a long-term cohort study with annual clinical visits, including blood sampling, neuropsychological testing, and brain magnetic resonance imaging (MRI). The results were compared with an age-and sex-matched cohort of healthy controls (HC). Correlations between BDNF levels and a range of clinical and magnetic resonance imaging variables were assessed using an adjusted linear model. Results: In total, 259 pwMS and 259 HC were included, with a mean age of 44.42 AE 11.06 and 44.31 AE 11.26 years respectively. Eleven had a clinically isolated syndrome (CIS), 178 relapsing remitting MS (RRMS), 56 secondary progressive MS (SPMS), and 14 primary progressive MS (PPMS). Compared with controls, mean BDNF levels were lower by 8 % (p˂0.001) in pwMS. The level of BDNF in patients with SPMS was lower than in RRMS (p = 0.004). Interpretation: We conclude that while the use of comparatively large cohorts enables the detection of a significant difference in BDNF levels between pwMS and HC, the difference is small and unlikely to usefully inform decision-making processes at an individual patient level.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis

Naegelin

Saeuberli

Schaedelin

et al. 2020

Ann Clin Transl Neurol

View full text Add to dashboard Cite

show abstract

“…Recent studies have also shown that brain-derived neurotrophic factor (BDNF) and soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) levels may serve as useful biomarkers for the diagnosis of MS [ 20 , 21 ].…”

Section: Multiple Sclerosis (Ms)mentioning

confidence: 99%

“…The potential biomarkers which can be used to predict the prognosis of relapsed or progressive forms of MS, as well as the responsiveness to treatment in patients with MS are SIRT1 (a NAD-dependent deacetylase sirtuin-1) mRNA, Response gene to complement-32 (RGC-32) , Fasl, IL-21, Tau proteins (proteins that stabilize microtubules), miR-191-5p, miR-128-3p and serum netrin-1 (an axon guidance protein) [ 17 , 21 , 29 , 30 , 31 , 32 ].…”

Section: Multiple Sclerosis (Ms)mentioning

confidence: 99%

Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review

Gul¹,

Jafari

Shah

et al. 2020

IJMS

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS) which can lead to severe disability. Several diseases can mimic the clinical manifestations of MS. This can often lead to a prolonged period that involves numerous tests and investigations before a definitive diagnosis is reached. As well as the possibility of misdiagnosis. Molecular biomarkers can play a unique role in this regard. Molecular biomarkers offer a unique view into the CNS disorders. They help us understand the pathophysiology of disease as well as guiding our diagnostic, therapeutic, and prognostic approaches in CNS disorders. This review highlights the most prominent molecular biomarkers found in the literature with respect to MS and its related disorders. Based on numerous recent clinical and experimental studies, we demonstrate that several molecular biomarkers could very well aid us in differentiating MS from its related disorders. The implications of this work will hopefully serve clinicians and researchers alike, who regularly deal with MS and its related disorders.

show abstract

Emerging imaging and liquid biomarkers in multiple sclerosis

et al. 2023

View full text Add to dashboard Cite

The advent of highly effective disease modifying therapy has transformed the landscape of multiple sclerosis (MS) care over the last two decades. However, there remains a critical, unmet need for sensitive and specific biomarkers to aid in diagnosis, prognosis, treatment monitoring, and the development of new interventions, particularly for people with progressive disease. This review evaluates the current data for several emerging imaging and liquid biomarkers in people with MS. MRI findings such as the central vein sign and paramagnetic rim lesions may improve MS diagnostic accuracy and evaluation of therapy efficacy in progressive disease. Serum and cerebrospinal fluid levels of several neuroglial proteins, such as neurofilament light chain and glial fibrillary acidic protein, show potential to be sensitive biomarkers of pathologic processes such as neuro‐axonal injury or glial‐inflammation. Additional promising biomarkers, including optical coherence tomography, cytokines and chemokines, microRNAs, and extracellular vesicles/exosomes, are also reviewed, among others. Beyond their potential integration into MS clinical care and interventional trials, several of these biomarkers may be informative of MS pathogenesis and help elucidate novel targets for treatment strategies.

show abstract

BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis

Abstract: BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS.

Cited by 35 publications

References 35 publications

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis

Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review

Emerging imaging and liquid biomarkers in multiple sclerosis

Contact Info

Product

Resources

About